ACADIA Pharmaceuticals Inc. (LON:0A4W)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 3.75B +21.6% |
| Revenue (ttm) | 858.20M +11.8% |
| Net Income | 286.77M +71.3% |
| EPS | 1.66 +66.4% |
| Shares Out | n/a |
| PE Ratio | 13.08 |
| Forward PE | 34.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 101 |
| Open | 26.87 |
| Previous Close | 18.62 |
| Day's Range | 26.87 - 26.87 |
| 52-Week Range | 16.31 - 26.87 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting sy... [Read more]
Financial Performance
In 2025, ACADIA Pharmaceuticals's revenue was $1.07 billion, an increase of 11.87% compared to the previous year's $957.80 million. Earnings were $391.00 million, an increase of 72.66%.
Financial numbers in USD Financial StatementsNews
Acadia Pharmaceuticals price target raised to $27 from $26 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $27 from $26 and keeps an Equal Weight rating on the shares.
Acadia Pharmaceuticals price target raised to $39 from $35 at Citi
Citi raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $39 from $35 and keeps a Buy rating on the shares.
Acadia Pharmaceuticals price target raised to $31 from $30 at BofA
BofA raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $31 from $30 and keeps a Buy rating on the shares. Following the Q2 report, the firm raised its…
Acadia Pharmaceuticals price target raised to $25 from $23 at Oppenheimer
Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $25 from $23 and keeps a Perform rating on the shares. The firm notes the company reported Q2 results…
Acadia Pharmaceuticals price target raised to $37 from $36 at RBC Capital
RBC Capital raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $37 from $36 and keeps an Outperform rating on the shares. Acadia delivered a strong update with Daybue…
Acadia Pharmaceuticals price target raised to $36 from $35 at Mizuho
Mizuho analyst Uy Ear raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $36 from $35 and keeps an Outperform rating on the shares.
Acadia Pharmaceuticals price target raised to $36 from $35 at Citizens
Citizens analyst Jason Butler raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $36 from $35 and keeps an Outperform rating on the shares. Acadia posted a strong Q2…
Acadia Pharmaceuticals reports Q2 EPS 18c, consensus 4c
Reports revenue $308M, consensus $295.52M. “Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growt...
ACADIA Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw 17% revenue growth to $308M, driven by DAYBUE (30% growth) and NUPLAZID (10% growth). Guidance for DAYBUE was raised, with strong U.S. uptake and a positive CHMP opinion paving the way for a European launch. Pipeline progress includes phase II completion for remlifanserin.
ACADIA Pharmaceuticals Slides: Q2 2026
ACADIA Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
ACADIA Pharmaceuticals Earnings release: Q2 2026
ACADIA Pharmaceuticals released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
ACADIA Pharmaceuticals Quarterly report: Q2 2026
ACADIA Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 4, 2026.
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026. “Acadia delivered an outstanding second quarte...
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, Augu...
Acadia Pharmaceuticals price target raised to $36 from $34 at BMO Capital
BMO Capital transferred its coverage on Acadia Pharmaceuticals (ACAD) to who raised the firm’s price target to $36 from $34 and keeps an Outperform rating on the shares. The analyst…
Acadia Pharmaceuticals price target raised to $25 from $24 at Stifel
Stifel analyst Paul Matteis raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $25 from $24 and keeps a Hold rating on the shares. While the firm thinks Acadia…
Acadia Pharmaceuticals price target raised to $25 from $24 at Stifel
Stifel analyst Paul Matteis raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $25 from $24 and keeps a Hold rating on the shares. Stifel believes Acadia has given…
Acadia Pharmaceuticals receives FDA Fast Track designation for remlifanserin
Acadia Pharmaceuticals (ACAD) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to remlifanserin, an investigational, highly selective, 5-HT2A receptor inve...
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin, an investig...
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S....
Acadia Pharmaceuticals price target raised to $36 from $29 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $36 from $29 and keeps an Outperform rating on the shares as part of a…
Acadia Pharmaceuticals appoints Carl Segerstorm as CPO
Acadia Pharmaceuticals (ACAD) announced the appointment of Carl Segerstrom as Chief People Officer. Carl will lead the company’s global people and culture strategy, supporting its next phase of growth...
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company's global...
Acadia Pharmaceuticals price target raised to $30 from $29 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $30 from $29 and keeps a Buy rating on the shares after the company announced a…
Acadia Pharmaceuticals price target raised to $37 from $32 at Deutsche Bank
Deutsche Bank analyst David Hoang raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $37 from $32 and keeps a Buy rating on the shares. The firm says Daybue…